Neurothrombectomy Devices Market Size & Share 2024 to 2032

Neurothrombectomy Devices Market Size

Neurothrombectomy Devices Market was valued at USD 659 million in 2023 and is anticipated to attain 7.3% CAGR from 2024 to 2032. Neurothrombectomy devices belong to the category of neurovascular devices, which is estimated to reach 7.5 billion by 2032, designed to mechanically remove blood clots from vessels within the central nervous system, serving a crucial role in the acute ischemic stroke management. The increasing global incidence of ischemic stroke is fueling demand for neurothrombectomy devices.

Furthermore, continued investments in research and development by industry players stimulate the exploration of cutting-edge technologies and surgical techniques, thereby enhancing the efficacy and safety of neurothrombectomy procedures. These resulting innovations not only contribute to improved patient outcomes but also position the neurothrombectomy market for sustained growth in the dynamic landscape of neurological interventions.

Neurothrombectomy Devices Market Trends

Growing awareness among healthcare professionals and the general public about neurological conditions, emphasizing the importance of timely intervention, contributes to the increased adoption of neurothrombectomy devices. Education and awareness campaigns, exemplified by initiatives like The Brain Awareness Campaign launched by The Dana Alliance for Brain and supported by the Society for Neuroscience, play a crucial role in propelling market growth.
 

• Through open houses, exhibits, lectures, workshops, and valuable resources, these campaigns actively engage the public in Brain Awareness Week events, webinars, and educational videos covering diverse brain-related topics. Thus, these initiatives play a crucial role in fostering market expansion.
   
• Furthermore, technological advancements in neurothrombectomy devices continuously enhance procedural safety and efficacy for stroke management.
   
• These innovations foster the development of specialized, patient-centric devices, integrating cutting-edge technologies like advanced imaging and robotics. This positions neurothrombectomy procedures at the forefront of minimally invasive interventions, enhancing precision and ultimately improving patient outcomes.
   

Neurothrombectomy Devices Market Analysis

The stent retrievers segment was worth USD 378 million in 2023. Its ascendancy is attributed to their exceptional efficacy in treating ischemic stroke.
 

• Stent retrievers renowned for their high success rates in mechanically removing blood clots. These devices swiftly restore blood flow in affected vessels, leading to improved patient outcomes.
   
• Moreover, extensive clinical validation, versatility in addressing various clot sizes, and continuous technological advancements contribute to their dominance.
   
• Furthermore, medical guidelines endorsing stent retrievers as a standard of care, coupled with positive physician experiences and superior patient outcomes, solidifies their preference in the neurothrombectomy landscape.

Learn more about the key segments shaping this market

Download Free PDF

Based on end-use, the hospitals and clinics segment garnered USD 463 million revenue in 2023.
 

• Hospitals and clinics take the lead in the neurothrombectomy devices market due to their centralized infrastructure, specialized expertise, and advanced imaging capabilities.
   
• These institutions provide a collaborative care environment, crucial for intricate neurothrombectomy procedures. Equipped with emergency services, post-procedure care infrastructure, and a commitment to regulatory standards, hospitals and clinics are well-positioned to address complex neurological conditions effectively.

U.S. neurothrombectomy devices market size surpassed USD 244 million in 2023 and is predicted to witness substantial market growth.
 

• The U.S. commands a leading position in the neurothrombectomy devices industry, stimulated by its advanced healthcare infrastructure, robust research and development landscape, and a high incidence of ischemic stroke.
   
• For instance, according to estimates from the Centers of Disease Control and Prevention, ischemic stroke accounts for around 87% of all strokes in the U.S., with 75% of cases occurring in individuals experiencing their first stroke. Annually, almost 800,000 Americans suffer from a stroke, ranking it as the fifth leading cause of death, with a mortality rate of 45.2 per 100,000 population.
   
• Thus, the country's strong emphasis on research and development, coupled with a high prevalence of ischemic strokes, fuels continuous advancements and widespread use of these devices.
   
• Furthermore, the presence of leading medical device manufacturers and a proactive approach to neurological healthcare further solidify the U.S.'s dominance in the market.
   

Neurothrombectomy Devices Market Share

The neurothrombectomy devices industry is consolidated, with key players including Medtronic Plc, Stryker Corporation, Penumbra, Inc., MicroVention, Inc. (Terumo Corporation) and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in February 2023, Penumbra, Inc. launched the lightning flash mechanical thrombectomy system following FDA clearance. This innovative system integrates Penumbra's Lightning intelligent aspiration technology, enhanced with dual clot detection algorithms. The Lightning Flash device is specifically designed for the swift removal of substantial blood clots, encompassing venous thrombus and pulmonary emboli. This approval expands the company's product portfolio, positioning it with a competitive edge in the market.
 

Neurothrombectomy Devices Market Companies

Some of the eminent market participants operating in the neurothrombectomy devices industry include:

• Medtronic Plc
• Stryker Corporation
• Penumbra, Inc.
• Johnson & Johnson
• MicroVention, Inc. (Terumo Corporation)
• Acandis GmbH
• Phenox Inc.(Wallaby Medical)
• Vesalio, LLC
• AngioDynamics, Inc.
• Abbott Laboratories
• Edward Lifesciences Corporation
• Boston Scientific Corporation
   

Neurothrombectomy Devices Industry News

• In February 2023, Phenox Inc., a subsidiary of Wallaby Medical, announced the FDA 510(k) clearance for its pRESET thrombectomy device, approved for acute ischemic stroke management. The pRESET product line, with over a decade of presence in Europe, received clearance in the U.S. market. This regulatory approval facilitated the expansion of the product's geographical reach, positioning the company for increased revenue.
   
• In June 2021, AngioDynamics, Inc. obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AlphaVac mechanical thrombectomy system. Engineered as an off-circuit, versatile mechanical aspiration thrombectomy device, the system was crafted for the non-surgical extraction of thrombi or emboli from the vasculature. This regulatory approval strategically situated the company with a competitive edge in the market.
   

This neurothrombectomy devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Stent retrievers
• Aspiration devices
• Snares
• Continuous flush catheter

Market, By End-use

• Hospitals and clinics
• Ambulatory surgical centers (ASCs)
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa